

Title (en)
LIGAND/LYTIC PEPTIDE COMPOSITIONS AND METHODS OF USE

Title (de)
ZUSAMMENSETZUNGEN AUS LIGAND UND LYTISCHEM PEPTID SOWIE ANWENDUNGSVERFAHREN

Title (fr)
COMPOSITIONS DE PEPTIDES LYTIQUES/LIGANDS ET LEURS PROCEDES D'UTILISATION

Publication
EP 0988048 A1 20000329 (EN)

Application
EP 98912077 A 19980327

Priority
• US 9806013 W 19980327
• US 4100997 P 19970327
• US 86915397 A 19970604
• US 5745697 P 19970903

Abstract (en)
[origin: WO9842365A1] Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes). Lysis of tumor cells is rapid. The two components -the ligand and the lytic peptide- may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

IPC 1-7
A61K 38/16

IPC 8 full level
A01K 67/02 (2006.01); **A23K 1/165** (2006.01); **A61K 38/00** (2006.01); **A61K 38/09** (2006.01); **A61K 38/17** (2006.01); **A61K 38/22** (2006.01); **A61K 38/24** (2006.01); **A61P 15/18** (2006.01); **A61P 31/12** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 7/23** (2006.01); **C07K 14/435** (2006.01); **C07K 14/575** (2006.01); **C07K 14/59** (2006.01); **C07K 14/655** (2006.01); **C07K 19/00** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12N 15/82** (2006.01)

CPC (source: EP)
A61K 38/09 (2013.01); **A61K 38/31** (2013.01); **A61K 38/34** (2013.01); **A61P 15/18** (2017.12); **A61P 31/12** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07K 7/23** (2013.01); **C07K 14/43563** (2013.01); **C07K 14/575** (2013.01); **C07K 14/59** (2013.01); **C07K 19/00** (2013.01); **C12N 15/8257** (2013.01); **A61K 31/137** (2013.01); **A61K 31/565** (2013.01); **A61K 31/568** (2013.01); **A61K 38/00** (2013.01); **C07K 2319/00** (2013.01)

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9842365 A1 19981001; AT E364392 T1 20070715; AU 6587998 A 19981020; CA 2283630 A1 19981001; CA 2283630 C 20110830; DE 69837915 D1 20070726; DE 69837915 T2 20080221; EP 0975354 A1 20000202; EP 0975354 A4 20030716; EP 0975354 B1 20070613; EP 0988048 A1 20000329; EP 0988048 A4 20030528; ES 2289775 T3 20080201; JP 2000514836 A 20001107; WO 9842364 A1 19981001

DOCDB simple family (application)
US 9806114 W 19980327; AT 98913218 T 19980327; AU 6587998 A 19980326; CA 2283630 A 19980327; DE 69837915 T 19980327; EP 98912077 A 19980327; EP 98913218 A 19980327; ES 98913218 T 19980327; JP 54602698 A 19980327; US 9806013 W 19980327